DESTINY-Breast03 Phase 3 Study Results
Prevalence
30
20
10
0
100
90
90
80
70
60
Prevalence of Fatigue and Alopecia
61
Fatigue
Cycle
T-DXD 257 258 254 252 247 242 227 225 215 213 203 197 191 182 175 172 167 160 153 149 138 138 126 117 105 97 85 76 62 50 44 40 31 27 22 19 17 17 10 8 8 5 21
T-DM1 261 252 221 209 189 175 181 150 138 133 118 108 93 87 78 73 68 63 59 58 52 51 48 43 41 39 36 30 22 18 16 13 11 6 5 5 4 3 3 2 2 0 00
100
90
90
Alopecia
80
70
60
50
40
30
20
10
0
1 2 3 4 5 6 1 8
10
Daiichi-Sankyo
DESTINY-Breast03
T-DXD (n = 257)
T-DM1 (n=261)
Cycle
T-DXD 257 256 254 252 247 242 227 225 215 213 203 197 191 182 175 172 167 160 153 149 138 136 126 117 105 97 85 78 82 50 44 40 31 27 22 19 17 17 10 8 8 5 2 1
T-DM1 261 252 221 209 189 175 161 150 138 133 118 108 93 87 78 73 88 83 59 58 52 51 48 43 41 39 38 30 22 18 18 13 11 8 5 5 4 3 3 2 2 0 0 0
The prevalence of fatigue and alopecia was relatively consistent over time
T-DM1, trastuzumab emtansine, T-DXd, trastuzumab deruxtecan.
Prevalence was defined as the number of patients who had the event starting at a particular cycle or still ongoing at that cycle divided by the number of patients on treatment at that cycle.
ASCO 2022 #1000 Oral
33View entire presentation